Turnspire Capital Partners Completes Acquisition of Pharmachem Innovations from Ashland

September 3, 2024

Turnspire Capital Partners has acquired Pharmachem Innovations, the former nutraceuticals business of Ashland Inc., creating an independent nutraceuticals platform. Pharmachem — a provider of proprietary nutrition ingredients, custom formulation and contract manufacturing with ~500 employees across facilities in New Jersey, Utah and Tamaulipas, Mexico — will be led by Executive Chairman Maurice Murphy and Interim CEO Jeff Rogers as Turnspire pursues operational growth opportunities.

Targets
Pharmachem Innovations, LLC
Sellers
Ashland Inc.
Industry
Food & Beverage
Location
New Jersey, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.